Core Viewpoint - He Yuan Bio, an unprofitable innovative pharmaceutical company, has listed on the Sci-Tech Innovation Board, challenging domestic and international blood product giants with its unique plant-based recombinant human albumin derived from rice [2][3]. Company Overview - He Yuan Bio's core product is "rice-derived blood," specifically the world's first plant-based recombinant human albumin, which is currently its only commercialized product. The company has incurred losses of 480 million yuan over the past three years [2]. - The IPO price was set at 29.06 yuan per share, aiming to raise approximately 2.6 billion yuan, with 1.657 billion yuan allocated for the construction of an industrialization base for recombinant human albumin [2]. Market Potential - The recombinant human albumin market in China was valued at 25.8 billion yuan in 2020, with projections of reaching 57 billion yuan by 2030. He Yuan Bio aims to capture nearly 20% of the domestic market [4]. - The company has established a commercial production line with an annual capacity of 10 tons and plans to expand to 120 tons by 2026 [4]. Competitive Landscape - He Yuan Bio's plant-based recombinant human albumin directly competes with human-derived blood products and aims to address the limited domestic blood plasma supply, which has led to a reliance on imports [3][4]. - The company claims that its product is safer due to the absence of blood plasma donation and has comparable efficacy to human-derived albumin [6]. Pricing Strategy - The current market price for He Yuan Bio's recombinant human albumin is 890 yuan per 10g, significantly higher than the 350-400 yuan range for human-derived products [6][9]. - The company anticipates that production costs will decrease with scale, and it plans to apply for inclusion in the medical insurance directory to potentially lower prices further [9]. Product Development - He Yuan Bio is currently focused on the clinical trial for its recombinant human albumin, with plans to complete Phase III trials in the U.S. by 2025 and submit for market approval in 2026 [5]. - Other products in development include recombinant human lactoferrin and recombinant human α-1 antitrypsin, with ongoing clinical trials for various indications [10].

Core Insights - The company reported a revenue of 2.717 billion, net profit attributable to shareholders of 317 million, and net profit excluding non-recurring items of 337 million for Q1-Q3 2025, showing a year-on-year change of +15.90%, -23.86%, and -6.74% respectively [1] - In Q3 2025, the company achieved a revenue of 986 million, net profit attributable to shareholders of 177 million, and net profit excluding non-recurring items of 147 million, with year-on-year changes of +16.83%, -7.93%, and +1.08% respectively [1] Operational Analysis - Core products are gaining traction, with EBITDA showing steady growth, and the launch of Ensartinib in the U.S. market [2] - The company currently has 8 marketed drugs, with sales growth driven by existing products and the gradual release of new products [2] - EBITDA for Q1-Q3 2025 reached 860 million, reflecting a year-on-year increase of +20.15% [2] - The innovative product Tarecitinib was approved for sale in China in June 2025, and Ensartinib opened its first prescription in the U.S. in August 2025, both expected to contribute to revenue growth [2] - Strategic collaborations and innovative ecosystem layouts are beginning to show results, with the nationwide sales of Trastuzumab starting in July 2025 [2] - The company has exclusive distribution rights for a new indication of a strategic investment project approved in July 2025 [2] - Key Phase III clinical trials for EYP-1901 have completed patient enrollment, with another trial starting in October 2025 [2] Research and Development Progress - Ongoing projects are advancing steadily, with the MCLA-129 Phase II study in lung cancer having completed its first patient enrollment [3] - Research data on Ensartinib and other studies have been presented at major academic conferences [3] Financial Forecast and Valuation - The company is expected to achieve revenues of 3.554 billion, 4.200 billion, and 5.193 billion for the years 2025, 2026, and 2027 respectively, with net profits of 563 million, 691 million, and 869 million [4] - The core business is projected to grow steadily, with operational management improving efficiency [4]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Insights - The company reported a revenue of 2.717 billion, a net profit attributable to shareholders of 317 million, and a net profit excluding non-recurring items of 337 million for the first three quarters of 2025, reflecting a year-on-year increase of 15.90% in revenue but a decrease of 23.86% in net profit [2] - The company has launched its innovative product Ensartinib in the US market and has eight drugs currently on sale, contributing to steady revenue growth [3] - The company’s EBITDA reached 860 million, representing a year-on-year increase of 20.15%, despite a decline in net profit due to rising depreciation and amortization expenses [3] - The company has made significant progress in its pipeline, with multiple academic results published and ongoing clinical trials for various treatments [4] Summary by Sections Performance Review - For Q3 2025, the company achieved a revenue of 986 million, a net profit of 177 million, and a net profit excluding non-recurring items of 147 million, with year-on-year changes of +16.83%, -7.93%, and +1.08% respectively [2] Operational Analysis - The company’s core products are gaining traction, and the EBITDA is showing robust growth. The launch of new products is expected to drive future performance [3] - Strategic collaborations and the establishment of an innovative ecosystem are beginning to yield results, with new treatments being approved and launched [3] Research and Development - The company is advancing its research projects steadily, with significant clinical trials and studies being conducted in various cancer treatment areas [4] Financial Forecast and Valuation - The company is projected to achieve revenues of 3.554 billion, 4.200 billion, and 5.193 billion for the years 2025, 2026, and 2027 respectively, with net profits of 563 million, 691 million, and 869 million [5]

Core Viewpoint - Benda Pharmaceutical experienced a decline of 5.01% in stock price, reaching 54.59 CNY per share, with a trading volume of 603 million CNY and a turnover rate of 2.60%, resulting in a total market capitalization of 22.968 billion CNY [1] Company Overview - Benda Pharmaceutical Co., Ltd. is located in Hangzhou, Zhejiang Province, and was established on January 7, 2003, with its listing date on November 7, 2016 [1] - The company's main business involves the research, production, and sales of pharmaceuticals, with 99.10% of its revenue coming from drug sales and 0.90% from other supplementary sources [1] Fund Holdings - According to data, one fund under GF Fund has a significant holding in Benda Pharmaceutical. The GF Stable Growth Mixed A Fund (002622) held 4,700 shares in the second quarter, accounting for 0.49% of the fund's net value, ranking as the fifth-largest holding [2] - The GF Stable Growth Mixed A Fund was established on June 27, 2016, with a latest scale of 55.5805 million CNY. Year-to-date returns are 4.55%, ranking 6963 out of 8155 in its category, while the one-year return is 4.95%, ranking 6942 out of 8029 [2] - The fund manager, Qiu Shilei, has been in position for 9 years and 276 days, with total assets under management of 552 million CNY. The best fund return during his tenure is 64.45%, while the worst is 0.28% [2]

Core Viewpoint - He Yuan Bio (688765.SH) has successfully listed on the Sci-Tech Innovation Board, marking it as one of the first newly registered companies in the growth sector of the board [1] Company Overview - He Yuan Bio was established in 2006 and specializes in research and product development of plant-derived recombinant protein expression technology [1] - The company is recognized as a national high-tech enterprise [1] Market Performance - On its first trading day, He Yuan Bio opened significantly higher, with an increase of 202.82%, starting at a price of 88 CNY per share [1] - By midday closing, the stock price rose by 202.96%, reaching 88.04 CNY per share, resulting in a total market capitalization of 31.474 billion CNY [1] Shareholders - The company's backers include notable entities such as Shanghai Tongsheng, Betta Pharmaceuticals, Optics Valley Biofund, Yifeng Capital, Xinxin Capital, Wanhua Hongyuan, and Huaxi Bio [1]

Core Viewpoint - The article discusses the successful listing of Wuhan Heyuan Bio on the Sci-Tech Innovation Board, marking a significant milestone in the revival of the board's fifth set of listing standards for unprofitable companies, particularly in the biotech sector [3][6]. Group 1: Industry Overview - The Sci-Tech Innovation Board has prioritized the biopharmaceutical industry since its inception in 2019, with a total market capitalization of 1.13 trillion yuan for 110 listed biopharmaceutical companies as of December 2024 [5]. - The biopharmaceutical sector faces challenges due to long R&D cycles, high investment costs, and low success rates, leading to a significant drop in IPOs from 36 in 2021 to just 1 in 2024 on the Sci-Tech Innovation Board [6]. - The reintroduction of the fifth set of standards has opened new capital windows for unprofitable hard-tech companies, with Heyuan Bio being the first to successfully list under these new guidelines [6][13]. Group 2: Company Highlights - Heyuan Bio specializes in plant-derived recombinant protein expression technology and has developed a product, Aofumin®, which is the first human serum albumin injection based on recombinant protein technology in China [11][12]. - The company has received significant strategic investments from various institutions, including Yifeng Capital, which has supported Heyuan Bio through multiple funding rounds, demonstrating a commitment to long-term investment [12][13]. - The successful listing of Heyuan Bio is seen as a validation of Yifeng Capital's strategic foresight and investment approach in the biopharmaceutical sector [20]. Group 3: Investment Insights - Yifeng Capital has been a key player in the recent successes of Heyuan Bio, North Chip Life, and Tainuo Maibo, showcasing its ability to identify and support promising biotech companies [7][20]. - The firm has built a robust investment strategy focused on long-term value creation, aligning with the principles of nurturing innovation and supporting the commercialization of scientific advancements [20]. - Yifeng Capital's CEO emphasizes the importance of time in developing innovative companies, positioning the firm as a "runner" alongside scientists rather than a short-term profit seeker [20].

Group 1 - BGI Pharmaceutical (300558.SZ) released its Q3 2025 report on October 28, 2025, indicating that 15 institutional investors hold a total of 196 million shares, accounting for 46.69% of the company's total equity [1] - The top ten institutional investors collectively hold 46.60% of the shares, with a 0.79 percentage point increase compared to the previous quarter [1] Group 2 - In the public fund sector, four funds increased their holdings, while two funds decreased their holdings, with a reduction rate of 0.23% [2] - Four new public funds were disclosed this period, while 523 funds were not disclosed compared to the previous quarter [2]

Financial Performance - The company's revenue for Q3 2025 reached ¥985,929,981.64, representing a 16.83% increase year-over-year[6] - Net profit attributable to shareholders decreased by 7.93% to ¥177,035,133.47 for the quarter, and by 23.86% to ¥316,932,355.32 for the year-to-date[6] - The net profit excluding non-recurring items was ¥146,603,519.66, a slight increase of 1.08% compared to the same period last year[6] - Operating income for the year-to-date was ¥2,717,342,723.91, up 15.90% due to increased pharmaceutical sales and the gradual release of new products[10] - Total operating revenue increased to ¥2,717,342,723.91, up from ¥2,344,643,009.24, representing a growth of approximately 15.9% year-over-year[26] - Net profit for the period was ¥303,006,092.01, down from ¥405,153,844.02, indicating a decline of approximately 25.3% year-over-year[27] - Earnings per share decreased to ¥0.76 from ¥0.99, representing a decline of about 23.2%[27] Assets and Liabilities - Total assets at the end of the quarter amounted to ¥9,699,462,636.70, reflecting a 3.83% increase from the end of the previous year[6] - The total assets increased to ¥9,699,462,636.70 from ¥9,341,677,723.81, showing a growth of approximately 3.8%[24] - The total liabilities increased to ¥3,779,901,199.51 from ¥3,675,567,489.25, reflecting a growth of about 2.8%[24] - The total owner's equity rose to ¥5,919,561,437.19 from ¥5,666,110,234.56, indicating an increase of approximately 4.5%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 29,537[12] - The largest shareholder, Ningbo Kaiming Investment Management Partnership, holds 19.03% of shares, equating to 80,064,000 shares[12] - Zhejiang Jihe Venture Capital holds 12.91% of shares, totaling 54,324,000 shares[12] - The top 10 shareholders collectively hold significant stakes, with the top four shareholders accounting for 41.14% of total shares[12] - The actual controller, Ding Li Ming, indirectly controls 21.39% of shares through partnerships[12] - The company has no changes in the top 10 shareholders due to securities lending or borrowing compared to the previous period[13] - There are no preferred shareholders or changes in restricted shares reported for this period[13] - The company has a total of 0 preferred shareholders at the end of the reporting period[13] - The total number of shares held by the top 10 unrestricted shareholders is 80,064,000 shares[12] - The company has not disclosed any related party transactions among shareholders outside of the top shareholders[12] Operational Highlights - The company reported a significant increase in accounts receivable by 229.24% to ¥324,186,069.06, attributed to increased sales and outstanding receivables[10] - The company launched eight products, including the recently approved drugs Enasatinib and Tarecitinib, contributing to revenue growth[15] - The company has strategic partnerships, including a collaboration with Hangzhou Bozhirui Biopharmaceutical Co., which commenced nationwide sales of a new product in July 2025[16] - The company is advancing clinical trials for several drugs, including MCLA-129, which has completed patient enrollment for a Phase II study in lung cancer[17] - The company reported a 2-year disease-free survival rate of 86.4% for Enasatinib in postoperative adjuvant therapy, significantly reducing the risk of disease recurrence[17] Cash Flow and Investments - Operating cash inflow for the current period was CNY 2,737,853,928.25, an increase of 7.43% from CNY 2,548,182,394.10 in the previous period[28] - Net cash flow from operating activities decreased to CNY 668,430,246.92, down 19.6% from CNY 831,340,738.79 in the previous period[28] - Cash outflow from investing activities totaled CNY 731,485,187.19, compared to CNY 783,733,321.62 in the previous period, indicating a decrease of 6.67%[28] - Net cash flow from financing activities was CNY 2,786,569.40, a significant improvement from a net outflow of CNY 200,294,076.80 in the previous period[29] - The total cash and cash equivalents at the end of the period decreased to CNY 414,329,858.11 from CNY 595,341,383.28, reflecting a decline of 30.4%[29] - Cash inflow from financing activities increased to CNY 809,946,278.00, up from CNY 483,600,000.00 in the previous period, representing a growth of 67.5%[29] - Cash outflow for purchasing goods and services rose to CNY 402,612,013.17, compared to CNY 207,021,761.38 in the previous period, marking an increase of 94.5%[28] - The company reported a cash inflow of CNY 90,716,752.84 from other operating activities, up from CNY 75,478,085.66, an increase of 19.5%[28] - The company’s cash flow from investment activities showed a net outflow of CNY 730,471,677.77, slightly improved from CNY 781,682,505.65 in the previous period[28] - The impact of exchange rate changes on cash and cash equivalents was a positive CNY 1,901,864.44, compared to a negative impact of CNY 6,019,687.56 in the previous period[29] Research and Development - The company reported a decrease in research and development expenses to ¥372,969,710.80 from ¥384,037,587.90, a decline of approximately 2.9%[26] - Long-term equity investments rose to ¥599,381,502.98 from ¥360,541,773.33, an increase of about 66.3%[23]

证券代码：300558 证券简称：贝达药业 公告编号：2025-068 | | | | | | | | 已质押股份 情况 | | | 未质押股份情况 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 持股数量 （股） | 持股 比例 | 本次质押前 质押股份 数量 （股） | 本次质押后 质押股份 数量 （股） | 占其所 持股份 比例 | 占公司 总股本 比例 | 已质押 股份限 售和冻 结、标 记数量 | 占已 质押 股份 比例 | 未质押 股份限 售和冻 结数量 （股） | 占未质 押股份 比例 | | 凯铭投资 | 80,064,000 | 19.03% | 53,079,904 | 55,051,404 | 68.76% | 13.08% | （股） 0 | 0 | 0 | 0 | | 贝成投资 | 9,924,563 | 2.36% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | 丁列明 | 1,024,238 | 0.24% | 0 | 0 | 0 | 0 | 0 ...

Summary of Key Points - On October 24, Benda Pharmaceutical executed a block trade of 238,300 shares, with a transaction value of 10.7449 million yuan, accounting for 1.97% of the total trading volume for the day [1][2] - The transaction price was 45.09 yuan per share, representing a discount of 20.81% compared to the market closing price of 56.94 yuan [1][2]